Blue Bear Ventures

Ayar Labs specializes in optical interconnect technology for AI infrastructure, developing co-packaged optics to accelerate data transfer.

Aluna is an award-winning spirometer that gives you control and confidence in your lung health, allowing users with asthma or cystic fibrosis to measure their lung health anytime, anywhere.

Coreshell Technologies offers high-performance silicon anodes at low costs.

GenEdit is developing innovative therapies through targeted delivery of genetic medicines, utilizing their proprietary NanoGalaxy delivery platform to overcome challenges in genetic medicine delivery.

Particella, Inc. (formerly DNAlite Therapeutics) is a preclinical biotechnology company that has developed an oral lipid nanoparticle technology to deliver nucleic acids to the intestinal epithelium.

Aether Biomachines develops advanced biotechnological platforms to engineer enzymes for cost-effective manufacturing of complex products, focusing on an industrial revolution through biotechnology.

BioAmp is working to counteract antibiotic resistance through the development of precision diagnostics, empowering physicians with the information they need to treat their patients with the right antibiotic the first time.

Correlia Biosystems creates proteomic tools to power data-driven biology. Their instruments offer microsample measurement abilities to open new data for applications such as small animal models and precision medicine.

ImpriMed is pioneering AI-driven precision medicine, helping oncologists and pharmaceutical companies connect the right drug to the right patient through personalized analytics and ex vivo drug sensitivity assays.

Unnatural Products is a California-based biotech company focused on innovative medicine development, aiming to tackle challenging medical targets.

YourChoice Therapeutics is a company focused on developing innovative therapeutic solutions.

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Early-stage deep tech venture firm focused on helping entrepreneurs commercialize scientific and technological breakthroughs to build durable, impactful companies.

Targets companies addressing labor shortages in manufacturing, construction, logistics, and food production; cutting healthcare costs from aging and chronic disease; and enabling sustainable food production for growing populations.

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.

Writes first institutional checks ($500k–$5M) at earliest stages for compute-applied chemistry and biology ventures (therapeutics, industrial biotech, climate, materials), led by an advanced-degree scientific team.